I'm glad you replied and I believe that Northwest has a very interesting future. In that you and I have led a few public companies in different industries, the biotech industry is not one that I have had the opportunity to manage. However, I do think I understand how the deal works for research institutions like Roswell Park, MD Anderson, Sloan Kettering… and the rest. Research institutions are funded by grants, contributions, donations…. The institutions' goal is to find a biotech company that can best represent their research technology by dispersing their technology throughout the biotech industry in a wide variety of treatments. That speaks volumes about what Roswell Park thinks about DCVAX Technology, especially after two years working to negotiate this transaction. The In-Licensing cost to Northwest bio of 2.3 million dollars and a 4% royalty on Northwest products sold in combination with Roswell Park Technology that conditions the tumor Micro environment for Dendritic cell expansion and efficacy is a very small percentage of the development costs associated with the Roswell Park technology. Therefore, relying solely on the 4% royalty means that Roswell Park is very confident that Northwest's DCVax dendritic cell based platform technology will be widely approved and accepted, thus distributing DCVax Technology and Roswell Park technology in a multitude of successful treatments, proving the patient demand in every aspect of dendritic cell based immunotherapy!!! AND proving Roswell Park's medical research and development capabilities, thus supporting Roswell's continued financing through grants, donations.....! AND SUPPORTING NORTHWEST BIO's REVENUE CREATION AND SUBSEQUENT EXPANSION OF THE COMPANY'S FRANCHISE VALUE THAT WILL BE FAVORABLY REFLECTED IN THE SHARE PRICE AS THE MARKET RAPIDLY ACCELERATES THE REALIZATION OF FUTURE NET REVENUES GENERATED BY ANTICIPATED GROWTH OF THE VAST ARRAY OF NEW PRODUCTS IN THE COMPANY'S EVER EXPANDING PRODUCT PIPELINE!!!
Cheers
BB
News 
Market Data 
Discover 
AI
